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Published by Elsevier Inc.CORRESPONDENCELetters to the EditorOmega-3 Fatty Acids and
Prevention of Atrial FibrillationIn their recent study, Macchia et al. (1) concluded that omega-3
polyunsaturated fatty acids did not signiﬁcantly decrease the rates
of recurrent atrial ﬁbrillation. However, there is an uncertainty in
interpreting the results of this study.
First, it is well-known that there is a different stereochemistry of
omega-3 polyunsaturated fatty acids if they were acquired from
differentmarine sources such asﬁsh oils andmammalian oils; omega-
3 polyunsaturated fatty acids in ﬁsh oils and mammalian oils occupy
the sn-2 and sn-1, 3 positions on the triacylglycerol molecule,
respectively, which could change the metabolism of omega-3 poly-
unsaturated fatty acids and lower the circulating levels of tri-
acylglycerols, probably causing results of randomized clinical trials
heterogeneous (1–3). The source of omega-3 polyunsaturated fatty
acids, therefore, could affect the results of the study byMacchia et al.
(1). However, the source of omega-3 polyunsaturated fatty acids was
not described in detail in the protocol and their study.
Second, it is postulated that omega-3 polyunsaturated fatty acids
could stabilize atherosclerotic plaque, possess the antithrombogenic
properties, and provoke nitric oxide–induced endothelial relaxation
(4), which is the so-called pleiotropic effect similar to that of statins
(5). In addition, omega-3 polyunsaturated fatty acids possessed the
potential antiarrhythmic properties similar to those of statins (6).
In the study by Macchia et al. (1), however, possible different
inﬂuences of omega-3 polyunsaturated fatty acids based on co-
interventions including statin therapy were not described and inter-
preted in detail. In fact, it could be very difﬁcult to assess an association
of omega-3 polyunsaturated fatty acids with the use of a statin.*Ze-Zhou Song, MS
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2010;381:1–13.ReplyIn his letter, Dr. Song raised concerns about source and compo-
sition of omega-3 polyunsaturated fatty acids (n-3 PUFAs) used in
our trial (1) and how this could affect the results of the
FORWARD (Randomized Trial to Assess Efﬁcacy of PUFA for
the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation)
trial. The product used in our trial was the same as that used in
several large clinical trials of n-3 PUFA supplementation (2,3) and
is the one approved by the U.S. Food and Drug Administration
and European Medicines Agency. One 1-g capsule per day of n-3
PUFA contained 850 to 882 mg of eicosapentaenoic acid and
docosahexaenoic acid as ethyl esters in the average ratio of 1:1$2.
The results are coherent and consistent with many other clinical
trials and systematic reviews showing that at these doses,
n-3 PUFA supplementation does not have an effect on atrial
ﬁbrillation (AF) relapse (4,5).
In his second point, he asked us to clarify the possible
interactions between n-3 PUFAs and statins in our trial. The
proportion of patients who were receiving statin treatment was
45% to 50% and was equally distributed among experimental
arms. There was no interaction between statins and n-3 PUFAs
for any of the pre-speciﬁed endpoints of the study, including
survival free of AF; death; and the composite of all-cause
mortality, nonfatal stroke, nonfatal acute myocardial infarction,
systemic embolism, development of heart failure, and severe
bleeding.*Alejandro Macchia, MD
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e005033.Body Mass Index, Central Obesity,
and Mortality Among
Coronary Disease Subjects
In their recent study, Coutinho et al. (1) concluded that normal
body mass index with central obesity was associated with the
highest risk of mortality in subjects with coronary artery disease.
However, there is an uncertainty in interpreting the results of
this study.
It is well known that medication use such as chronic statin
therapy is closely associated with overall mortality in subjects
with coronary artery disease or other cardiovascular diseases such
as stroke and that subjects with obesity are more likely to be
treated by use of medication such as chronic statin therapy
because of metabolic abnormalities. In the study by Coutinho
et al. (1), however, medication use such as chronic statin therapy
was not described in detail, and the development of parsimo-
nious Cox model was not adjusted for medication use such as
chronic statin therapy. That is to say, medication use such as
chronic statin therapy was not discussed in detail, which could
have confounded the relationship of obesity to mortality in
subjects with coronary artery disease. In addition, many other
factors, which are well known to confound the relationship of
obesity to mortality in subjects with coronary artery disease or
other cardiovascular diseases such as strokedfor example,
including but not limited to the history of change of weight, the
condition of diet, weight loss, psychosocial stress, socioeconomicstatus, and physical activitydwere not described in detail in the
study by Coutinho et al. (1). Therefore it is unclear whether
normal body mass index with central obesity is associated with
the highest risk of mortality in subjects with coronary artery
disease when the above-mentioned factors, which might
confound the relationship of obesity to mortality, are taken into
account.*Ze-Zhou Song, MS
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Cardiol 2013;61:553–60.ReplyWe thank Profs. Song, Wang, and Zhang for their interest in our
study (1).
Because our study was a meta-analysis with individual patient
data, information on statins was not uniformly available in all
studies included, and for this reason the use of statins was not
originally included in the models as a potential confounder.
Multivariable Cox proportional hazard models in the 6,313 of
the 15,547 participants with data on statin use and including
statin use as covariate showed that normal-weight central obesity
still had the highest mortality among all participants (analyses
not shown). Furthermore, in the setting of secondary prevention,
the relative risk reduction attributed to statins is approximately
20% (2), representing an association of lesser magnitude than the
increased risk found with normal-weight central obesity. Thus, it
is unlikely that the results of our study were driven by differences
in statin use among subjects with different body adiposity
patterns.
We recognize that there might be some residual confounding
attributed to differences among groups in weight change over time,
diet, psychosocial stress, socioeconomic status, and physical activity.
Unfortunately, we had limited information on these factors to
completely adjust in the multivariate models. However, we are not
aware of any evidence suggesting that subjects with normal-weight
central obesity would be more stressed, poorer, less likely to lose
weight, or have worse nutrition than people with general obesity or
other patterns of fat distribution, to suspect that these variables
would explain all of the association between normal-weight central
obesity and higher mortality.Thais Coutinho, MD
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